Clinical utility analysis of the Hoxb8 mast cell activation test for the diagnosis of peanut allergy

BackgroundPeanut allergy is among the most severe and common food allergies. The diagnosis has a significant impact on the quality of life for patients and their families. An effective management approach depends on accurate, safe, and easily implementable diagnostic methods. We previously developed a cell-based assay using Hoxb8 mast cells (Hoxb8 MCs) aimed at improving clinical allergy diagnosis. In this study, we assessed its diagnostic performance by measuring blinded sera from a prospectively enrolled and pre-validated peanut allergy cohort.MethodsHoxb8 MCs were passively sensitized with sera from peanut-allergic and peanut tolerant children and adolescents (n = 112). Degranulation of Hoxb8 MCs was quantified upon stimulation with dose-titrated peanut extract by means of flow cytometry, using CD107a as activation marker. The results from the Hoxb8 mast cell activation test (Hoxb8 MAT) were compared to established diagnostic assays such as the skin prick test (SPT), specific IgE (sIgE) levels, and the basophil activation test (BAT). Additionally, serum samples from BAT nonresponders were assessed with the Hoxb8 MAT.ResultsHoxb8 MAT displayed a robust dose-dependent activation to peanut extract, with a cutoff value of <= 5.2% CD107a positive cells. The diagnostic accuracy was highest at allergen concentrations >= 100 ng/mL, with an area under the receiver operating characteristic curve (AUROC) of 0.97, 93% sensitivity, and 96% specificity, outperforming traditional SPT and sIgE tests. When compared to BAT, Hoxb8 MAT exhibited comparable diagnostic efficacy. Moreover, sera from BAT nonresponders were accurately classified into allergics and nonallergics by the Hoxb8 MAT.ConclusionsThe Hoxb8 MAT demonstrated a very good diagnostic precision in patients prospectively assessed for peanut allergy comparable to the fresh whole blood-based BAT. Additionally, it demonstrated its value for accurate classification of BAT nonresponders into allergic and nonallergic individuals. Further investigations into its utility in the routine clinical setting are warranted. The Hoxb8 MAT demonstrates high diagnostic accuracy, as determined by measuring blinded sera from a prospectively enrolled, prevalidated peanut allergy cohort. Similar to the BAT, the Hoxb8 MAT distinguishes between allergic and nonallergic patients who underwent clinically indicated OFCs to peanut. Additionally, it has the ability to accurately classify sera from BAT nonresponders. BAT, basophil activation test; Hoxb8, homebox b 8; MAT, mast cell activation test; MCs, mast cells; OFCs, oral food challenges; sIgE/sIgG, specific IgE/IgG; SPT, skin prick test.image